Navigation Links
KaloBios Provides Update on KB001-A Partnership and Clinical Status
Date:7/28/2014

nd are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

Forward Looking Statements
This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and statements regarding the company's clinical development of KB001-A, KB004 and KB003. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the potential timing and outcomes of clinical studies of KB001-A and KB004 undertaken now or in the future; the potential, if any, for future development of KB003; the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's ability to successfully progress, partner or complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining r
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
2. KaloBios Pharmaceuticals Completes Initial Public Offering
3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
8. KaloBios to Present at Needham Healthcare Conference
9. KaloBios Reports First Quarter 2013 Financial Results
10. KaloBios to Present at Stifel Healthcare Conference 2013
11. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
(Date:11/26/2014)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... report by IQ4I Research and Consultancy focusing on the ... more about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Pharmaceutical Ingredients Global Market – Forecast to 2020 ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
(Date:11/28/2014)... The Alternative Health Therapies ... past five years. The industry has been buoyed ... are either alternative to conventional Western medicine or ... analyst David Whytcross, “industry revenue has been further ... health insurance membership.” Meanwhile, improving economic conditions following ...
(Date:11/28/2014)... (HealthDay News) -- Celebration can quickly turn to ... Day, experts say. Over the last decade, more ... while people were using turkey fryers, according to the ... cared for a patient who tried to deep fry ... in any circumstances," Dr. Arthur Sanford, a burn surgeon ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin ... parabens and other cancer-causing agents, but they are also ... awareness programs that help in the fight against breast ... an incredible, record-breaking contribution of $30,000 through participation in ... Sweet Red Rose Whip Moisturizer and the company’s corporate ...
(Date:11/28/2014)... 28, 2014 Earlier in the ... the hugely popular, 2014 MTV Video Music Awards ... launched ground-breaking celebrity centered television advertisements directed at ... figures were estimated by Entertainment Weekly ... the spotlight on celebrities photographed by paparazzi smoking. ...
(Date:11/28/2014)... A newly released article from Community Health ... virus that will soon be spreading across the United States ... with a brief explanation of what the influenza virus is ... children under the age of 5, adults over the age ... heart and lung diseases, asthma, or diabetes, are at higher ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... Additional leadership needed to manage growthWAYNE, Pa. March 10 ... software, workflow tools and consulting services, is adding two ... line in order to best manage its growing client ... Vice President of Audit and Education Services and James ...
... 10 More physician leaders are embracing technological advances, ... them clunky and unresponsive to their needs.Those are the ... College of Physician Executives (ACPE). The findings were published ... ACPE,s journal of medical management.ACPE conducted the same survey ...
... LCAV ) today announced that following a rigorous clinical comparison ... to reduce the number of platforms at each of its ... The Company expects this will reduce annual operating expenses in ... no later than the end of the third quarter of ...
... 10, 2009 Forest Laboratories, Inc. (NYSE: FRX ... KGaA, and Merz Pharmaceuticals GmbH announced today that the U.S. ... Determination granting the full five years of patent term extension ... listed in the U.S. Food and Drug Administration Orange Book ...
... Safety Week, the spotlight shifts to the 30,000 dental assistants ... who help ensure that sedation dentistry is as safe for ... much an all-team responsibility," says Dr. Michael Silverman, national chairman ... sedation dentistry educators. , ...
... signs multi-year agreement with PureWellness to provide comprehensive employee wellness program ... ... 2009 -- PureWellness, Inc, a leading provider of online wellness solutions, ... in Plano, TX, to provide a comprehensive online wellness program for ...
Cached Medicine News:Health News:Precyse Solutions Adds Executives, Realigns Around Service Lines 2Health News:Survey Results: Health Care Technology Advances as Physician Frustration Grows 2Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 2Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 3Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 4Health News:USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R) 2Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 2Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 3Health News:Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness 2Health News:Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: